Mumbai, Aug. 14 -- Zydus Lifesciences announced that its formulation manufacturing facility located in Baddi, Himachal Pradesh, has received four observations from the United States Food and Drug Administration (USFDA).

According to an exchange filing, the company stated that the USFDA concluded a surveillance inspection at the Baddi facility, which was conducted from 4 August to 13 August 2025. The inspection ended with four observations.

The company clarified that none of the observations were related to data integrity. Zydus added that it will work closely with the USFDA to address and resolve the observations expeditiously.

In a separate filing, the company also informed that the USFDA conducted a Pre-Approval Inspection (PAI) at i...